After a late-stage miss, Novartis touts another Entresto analysis to convince the FDA to expand the blockbuster's label
Fresh after getting its keenly watched sickle cell treatment endorsed by the FDA, Novartis is pulling out all the stops to expand the use of heart therapy Entresto using a raft of analyses after the drug “narrowly” failed a crucial late-stage test.
Entresto is a top seller for Novartis and is currently approved for HFrEF (formerly known as systolic heart failure) — in these patients the heart muscle does not contract effectively, reducing the level of oxygen-rich blood pumped into to the body. The drug is administered twice daily and is designed to cut the strain on the failing heart.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.